CGP uses advanced next-generation sequencing (NGS) technologies to analyze DNA and RNA from tumor samples. The process starts with the extraction of genetic material from a biopsy. The genetic material is then sequenced, and bioinformatics tools are employed to interpret the data. This comprehensive analysis covers hundreds of genes, providing a broad view of the tumor's molecular landscape.
